Grant: Master's Award: Canada Graduate Scholarships
University of Manitoba
$17,500.00
Investigating the Role of Lymphocyte Activating Gene-3 (LAG-3) in HIV Susceptibility
FY 2020-21
Summary
Over 38 million people are still infected with HIV (Human Immunodeficiency Virus) to this day, despite the use of antiretroviral therapy to combat HIV infection. Like a lock and key, the virus uses CD4 on human T-cells to attach and enter cells, for infection. Specifically, HIV's envelope protein, gp120, binds to its main receptor, CD4, and then to a host chemokine receptor enabling viral and host membranes to fuse, which allows the virus to enter cells. Lymphocyte activation gene-3 (LAG3) is a strong candidate as a surface receptor for HIV due to its high structural similarity to CD4, based on DNA sequence and function in binding shared molecules. Therefore, LAG3 can be thought of as CD4's evil twin serving as an alternative lock for HIV entry. LAG3 is an immune checkpoint (IC) molecule which inhibits the activation and functions of immune cells so the cell doesn't over react and cause harm to the host. Thus, such IC molecules serve as the breaks of immune system. Compared to other ICs, LAG3 is highly expressed on HIV-infected cells. So, is LAG3 enhancing viral entry, given its high similarity to CD4? If we block the LAG3 receptors used for entry of virus, could this be used to decrease, if not prevent, HIV infection? Hence, we aim to understand LAG3's role in HIV viral entry and discover ways to block these surface molecules to limit the HIV susceptibility of cells. Doing so would collectively reduce disease severity by not only blocking viral entry, but also reinvigorating the function of these immune cells to help the immune system in clearing HIV when HIV therapy is administered to patients. Thus, the ability to alleviate HIV susceptibility by blocking LAG3 could inform and augment current cure strategies and ultimately relieve the burden of HIV/AIDs globally.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449542
Name
Mohideen Shifa F
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Role of Lymphocyte Activating Gene-3 (LAG-3) in HIV Susceptibility
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Lag-3 Antibody Blockade; Cd223; Hiv Immunotherapy; Hiv Receptors; Hiv Susceptibility; Immune Checkpoint Molecules; Inhibitory Receptors; Lymphocyte Activation Gene-3; T-Cell Exhaustion And Dysfunction; Viral Entry
Abstract
Over 38 million people are still infected with HIV (Human Immunodeficiency Virus) to this day, despite the use of antiretroviral therapy to combat HIV infection. Like a lock and key, the virus uses CD4 on human T-cells to attach and enter cells, for infection. Specifically, HIV's envelope protein, gp120, binds to its main receptor, CD4, and then to a host chemokine receptor enabling viral and host membranes to fuse, which allows the virus to enter cells. Lymphocyte activation gene-3 (LAG3) is a strong candidate as a surface receptor for HIV due to its high structural similarity to CD4, based on DNA sequence and function in binding shared molecules. Therefore, LAG3 can be thought of as CD4's evil twin serving as an alternative lock for HIV entry. LAG3 is an immune checkpoint (IC) molecule which inhibits the activation and functions of immune cells so the cell doesn't over react and cause harm to the host. Thus, such IC molecules serve as the breaks of immune system. Compared to other ICs, LAG3 is highly expressed on HIV-infected cells. So, is LAG3 enhancing viral entry, given its high similarity to CD4? If we block the LAG3 receptors used for entry of virus, could this be used to decrease, if not prevent, HIV infection? Hence, we aim to understand LAG3's role in HIV viral entry and discover ways to block these surface molecules to limit the HIV susceptibility of cells. Doing so would collectively reduce disease severity by not only blocking viral entry, but also reinvigorating the function of these immune cells to help the immune system in clearing HIV when HIV therapy is administered to patients. Thus, the ability to alleviate HIV susceptibility by blocking LAG3 could inform and augment current cure strategies and ultimately relieve the burden of HIV/AIDs globally.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mohideen, Shifa F
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~